Early anticoagulation in the current management of NSTE-ACS: Evidence, guidelines, practice and perspectives

Mattia Galli, Italo Porto, Felicita Andreotti, DOMENICO D'AMARIO, Rocco Vergallo, Roberta Della Bona, Filippo Crea

Research output: Contribution to journalLiterature reviewpeer-review

Abstract

Anticoagulant therapy during the acute phase of non-ST elevation acute coronary syndromes (NSTE-ACS) is strongly recommended by current international guidelines. Evidence supporting the use of anticoagulant therapy in the early phase of NSTE-ACS however, is based on dated trials mostly performed in the nineties and recent randomised clinical trials (RCTs), performed during the last 15 years, clearly evidence a dichotomy in the investigation of antiplatelet and anticoagulant strategies. Many innovations have since occurred in the diagnosis and management of NSTE-ACS. Since a RCT evaluating the efficacy of anticoagulant therapy versus placebo in a contemporary setting of NSTE-ACS management is lacking, we provide a systematic review of 1) the randomised data for ATT in the early phase of NSTE-ACS; 2) modern international guidelines, and 3) contemporary clinical practice data. The results are analysed and potential treatment and research strategies are proposed. (c) 2018 Elsevier B.V. All rights reserved.
Original languageEnglish
JournalInternational Journal of Cardiology
Volume275
DOIs
Publication statusPublished - 2019

Keywords

  • Anticoagulants
  • Early phase
  • Modern management
  • NSTE-ACS

Fingerprint

Dive into the research topics of 'Early anticoagulation in the current management of NSTE-ACS: Evidence, guidelines, practice and perspectives'. Together they form a unique fingerprint.

Cite this